|Bid||64.83 x 900|
|Ask||64.84 x 1300|
|Day's range||64.60 - 65.46|
|52-week range||63.07 - 81.44|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||18.84|
|Forward dividend & yield||2.28 (3.50%)|
|Ex-dividend date||06 Apr 2023|
|1y target est||N/A|
Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...
NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.
Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Its hefty yield isn't the only reason to consider buying this top pharma stock.
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Let's consider the case of Bristol Myers Squibb (NYSE: BMY). The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest.
There has been no shortage of companies cutting dividends in the past year. If you're looking for some safety on the dividend front, consider Bristol Myers Squibb (NYSE: BMY), Verizon Communications (NYSE: VZ), and Coca-Cola (NYSE: KO).
In the last year, many Bristol-Myers Squibb Company ( NYSE:BMY ) insiders sold a substantial stake in the company which...
When it comes to large and fairly complicated companies such as Bristol-Myers Squibb, (NYSE: BMY), the most knowledgeable investors tend to see a lot of things that casual observers miss. With that perspective in hand, let's explore three less-than-obvious things about Bristol-Myers that smart investors probably know, so that you'll have the benefit of their observations. Smart investors appreciate that Bristol-Myers isn't going to be expanding very much in the near term as a result of one of its big-earning medicines losing its exclusivity protections.